The U.S. Department of Justice's National Fraud Enforcement Division has implemented Directive 26-12, a policy update effective October 1, 2026, designed to streamline the prosecution of corporate fraud. This directive introduces a new, centralized Corporate Enforcement Section (CES) tasked with coordinating investigations and ensuring uniform application of enforcement policies across key areas.
Centralized Enforcement Focus
Under Assistant Attorney General Colin M. McDonald, the Fraud Division is adopting a proactive approach, prioritizing four core areas: healthcare fraud, procurement and government contract fraud, significant tax evasion, and trade-related misconduct, including tariff evasion and the use of forced labor. The CES aims to break down traditional bureaucratic barriers to facilitate more effective large-scale corporate investigations.
The directive emphasizes the use of data analytics and whistleblower incentives. Prosecutors are now required to liaise with the CES on significant developments in ongoing cases, ensuring alignment with the DOJ's strategic enforcement objectives. This centralization is expected to lead to more consistent and impactful enforcement actions.
Implications for Corporate Compliance
Directive 26-12 outlines ten factors prosecutors will consider when deciding on charges or resolutions, offering greater transparency for corporate compliance programs. While this provides a clearer understanding of compliance expectations, it also heightens the risk associated with inadequate internal controls and the potential for whistleblower reports. The DOJ continues to encourage voluntary disclosures, reinforcing the importance of robust internal monitoring and stress-testing compliance systems.
This initiative suggests a refined focus on early detection of misconduct. For businesses and investors, the directive underscores the critical need for stringent internal oversight and highlights the increased legal ramifications of overlooking early indicators of fraud.
Original reporting by Sullivan & Cromwell LLP. This article is desk analysis prepared by The Forensic Ledger from publicly available sources, summarized with citation to the original.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.
